Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price fell 31.6% during mid-day trading on Wednesday . The stock traded as low as C$0.10 and last traded at C$0.13. 130,060 shares traded hands during mid-day trading, an increase of 595% from the average session volume of 18,703 shares. The stock had previously closed at C$0.19.
Devonian Health Group Stock Performance
The firm has a fifty day moving average of C$0.16 and a 200-day moving average of C$0.19. The firm has a market cap of C$20.75 million, a P/E ratio of -7.00 and a beta of 1.28. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Further Reading
- Five stocks we like better than Devonian Health Group
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- How to Plot Fibonacci Price Inflection Levels
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- 3 REITs to Buy and Hold for the Long Term
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
